


## **₯S**terne Kessler Goldstein Fnx

ATTORNEYS AT LAW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald I. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim

Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Albert L. Ferro\* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian I. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier

July 21, 2005

Rae Lynn P. Guest Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Aris W. Ledford Aric W. Ledford Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersole Laura A. Vogel

Michael J. Mancuso Bryan S. Wade Aaron L. Schwartz Michael G. Penn\* Shannon A. Carroll\* Wesley W. Jones\* Matthew E. Kelley\* Nicole R. Kramer\*

Registered Patent Agents • Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella Jeffrey S. Lundgren Victoria S.Rutherford

Michelle K. Holoubel Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills

Fvan R Smith Marvin C. Guthrie

\*Admitted only in Maryland \*Admitted only in Virginia Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8619 **INTERNET ADDRESS:** SCHWARTZ@SKGF.COM

Mail Stop: Amendment

Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Appl. No. 10/826,909; Filed: April 19, 2004

Methods of Treating Diseases Responsive to Induction of Apoptosis

and Screening Assays

Inventors:

Kasibhatla et al.

Our Ref:

1735.0840002/RWE/ALS

Sir:

Applicants submit the following documents for appropriate action by the U.S. Patent and Trademark Office:

- 1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. Two (2) pages of Form PTO/SB/08B citing sixteen (16) documents;
- 3. Copies of the sixteen (16) cited documents; and
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz Attorney for Applicants Registration No. 48,181

RWE/ALS/law Enclosures

423706 1.DOC

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



In re application of:

Kasibhatla et al.

Appl. No.: 10/826,909

Filed: April 19, 2004

For: Methods of Treating Diseases Responsive to Induction of Apoptosis

and Screening Assays

Confirmation No.: 1721

Art Unit: 1614

Examiner: To be assigned

Atty. Docket: 1735.0840002/RWE/ALS

## First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents NPL1-NPL16 are submitted herewith.

This paper IDS is supplemental to an electronic IDS concurrently filed today. Any fee necessary for consideration of this Supplemental IDS has been authorized or otherwise submitted with the electronic IDS.

Applicants would also like to bring to the attention of the Examiner that, for the following documents, the day of publication could not be determined to the best of the Applicants' ability: **NPL10**, Abstract of Szekeres, T., et al., "Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells," *Curr. Med. Chem.* 9:759-764, Bentham Science Publishers Ltd. (April 2002).

With the exception of document NPL10, where the publication date of a listed document does not provide a month or date of publication, the year of publication of the listed document is sufficiently earlier or later than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz
Attorney for Applicants
Registration No. 48,181

Date: July 21, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

408182\_1.DOC

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
FIDOT CUD	mr ma	e en el e	r a t	Application Number	10/826,909		
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE				Filing Date	April 19, 2004		
				First Named Inventor	Kasibhatla, S.		
STATEMENT BY APPLICANT				Art Unit	1614		
(Use as many sheets as necessary)			is necessary)	Examiner Name	To be determined		
Sheet	1	of	2	Attorney Docket Number	1735.0840002/RWE/ALS		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Abstract of Bridge, J.A., et al., "Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor," Am. J. Pathol. 159:411-415, The American Society for Investigative Pathology (2001)	
	NPL2	Abstract of Geminard, C., et al., "Reticulocyte maturation: mitoptosis and exosome realease," Biocell 26:205-215, Instituto de Histología y Embriología (August 2002)	
	NPL3	Abstract of Hayashida-Hibino, S., et al., "The effect of TGF-beta1 on differential gene expression profiles in human corneal epithelium studied by cDNA expression array," Invest. Ophthalmol. Vis. Sci. 42:1691-1697, The Association for Research in Vision and Ophthalmology (2001)	
	NPL4	Abstract of Kalivendi, S.V., et al., "1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide," <i>Biochem. J.</i> 371:151-164, American Chemical Society (April 1, 2003)	
	NPL5	Abstract of Kedra, D., et al., "Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11," <i>Hum. Mol. Genet.</i> 5:625-631, Oxford University Press (1996)	
	NPL6	Abstract of Lesnikov, V., et al., "Pro-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes," <i>Exp. Hematol.</i> 29:477-489, International Society for Experimental Hematology and Elsevier Science, Inc. (2001)	
	NPL7	Abstract of Matsushima, T., et al., "Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells," <i>Blood 98</i> :313-321, American Society of Hematology (2001)	
	NPL8	Abstract of Prescott, JL and Tindall, D.J., "Clathrin gene expression is androgen regulated in the prostate," <i>Endocrinology</i> 139:2111-2119, The Endocrine Society (1998)	
	NPL9	Abstract of Pushkareva, M.Y., et al.,"Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine," Cancer Immunol. Immunother. 48:569-578, Springer-Verlag GmbH (2000)	
	NPL10	Abstract of Szekeres, T., et al., "Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells," Curr. Med. Chem. 9:759-764, Bentham Science Publishers Ltd. (April 2002)	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
Substitute for	UIII 1443/1 IV	•		Application Number	10/826,909
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE				Filing Date	April 19, 2004
				First Named Inventor	Kasibhatla, S.
STATEN	TENT BY	, API	PLICANT	Art Unit	1614
STATEMENT BY APPLICANT (Use as many sheets as necessary)			s necessary)	Examiner Name	To be determined
Sheet	12	of	2	Attorney Docket Number	1735.0840002/RWE/ALS

Examiner Initials*	Cite No. <sup>1</sup>	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL11	Abstract of Tampo, Y., et al., "Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis," <i>Circ. Res.</i> 92:56-63, Lippincott Williams & Wilkins (January 2003)	
	NPL12	Abstract of Thompson, K., et al., "Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress," J. Neurosci. Res. 71:46-63, John Wiley & Sons, Inc. (January 2003)	
	NPL13	Abstract of Touriol, C., et al., "Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)," <i>Blood</i> 95:3204-3207, American Society of Hematology (2000)	
	NPL14	Abstract of Vaughan, A.T., et al., "The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system," Int. J. Radiat. Oncol. Biol. Phys. 8:1943-1946, Elsevier Inc.(1982)	_
	NPL15	Abstract of Yen, C.F., et al., "Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells," <i>Biochim. Biophys. Acta.</i> 1257:47-57, Elsevier B.V. (1995)	
	NPL16	Trowbridge, I.S., et al., "Structure-Function Analysis of the Human Transferrin Receptor: Effects of Anti-Receptor Monoclonal Antibodies on Tumor Growth," Curr. Stud. Hematol. Blood Trans. 58:139-147, Karger (1991)	

E miner	Date	1
Examiner	Considered	· ·
Signature	U 11250 000 De	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uncluding gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.